PureTech Health (NASDAQ:PRTC – Get Free Report) is anticipated to post its H1 2026 resultson Thursday, August 27th. Analysts expect PureTech Health to post earnings of ($1.16) per share and revenue of $24.80 million for the quarter. Parties are encouraged to explore the company’s upcoming H1 2026 earning summary page for the latest details on the call scheduled for Friday, September 4, 2026 at 3:00 AM ET.
PureTech Health Price Performance
NASDAQ PRTC opened at $17.42 on Wednesday. PureTech Health has a 52 week low of $14.50 and a 52 week high of $19.92. The stock’s 50-day moving average price is $17.42 and its 200-day moving average price is $17.24.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in PureTech Health stock. Pentwater Capital Management LP lifted its holdings in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC – Free Report) by 50.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 75,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. Pentwater Capital Management LP owned 0.31% of PureTech Health worth $1,388,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.04% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on PRTC
About PureTech Health
PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.
PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.
Read More
- Five stocks we like better than PureTech Health
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
